Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy
Background: Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy; however, there is no evidence to guide optimal treatment choice. Objective: We aimed to compare add-on cyproterone acet...
Main Authors: | Lachlan Angus, Shalem Leemaqz, Olivia Ooi, Pauline Cundill, Nicholas Silberstein, Peter Locke, Jeffrey D Zajac, Ada S Cheung |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2019-07-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | https://ec.bioscientifica.com/view/journals/ec/8/7/EC-19-0272.xml |
Similar Items
-
Recommendations for the Use of Testosterone in Male Transgender*
by: Laura Bregieiro Fernandes Costa, et al.
Published: (2018-05-01) -
Personalized character of transgender medicine as a barrier to development of evidence-based clinical practice guidelines on gender incongruence
by: Ya. Kirey-Sitnikova
Published: (2022-09-01) -
Socio-demographic portrait of transsexual patients in Russia
by: N. V. Solov’eva, et al.
Published: (2019-04-01) -
Access to care and frequency of detransition among a cohort discharged by a UK national adult gender identity clinic: retrospective case-note review
by: R. Hall, et al.
Published: (2021-11-01) -
Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study
by: Lucas Foster Skewis, et al.
Published: (2021-07-01)